Proof of Usefulness Report

Endece

Analysis completed on 2/6/2026

+38
Proof of Usefulness Score
You're In Business

Endece is a legitimate pharmaceutical entity founded in 2006, holding patents for NDC-1308 targeting ARDS and MS. However, the project submission contains verifiably false traction claims (e.g., 'most people have used my product'), whereas independent data confirms the drug is still in pre-clinical or early investigational stages as of late 2022. The 20-year development timeline with no approved product and the low-quality submission significantly reduce the score.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+56.0
Audience Reach Impact+5.0
Technical Innovation+65.0
Evidence Of Traction+0.0
Market Timing Relevance+45.0
Functional Completeness+5.0
Subtotal+29.5
Usefulness Multiplierx1.10
Final Score+32

Project Details

Project URL
endece.com
Description
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition resulting in a reduction of oxygen that reaches the blood stream and vital organs. Few effective therapeutic modalities exist to treat ARDS, leading to a high mortality rate. ENDECE designed NDC-1308 to reduce the ability of SARS-CoV-2 / COVID-19 to replicate within the pulmonary system, and reduce inflammation.

Algorithm Insights

Market Position
Growing utility with room for optimization
User Engagement
Documented reach suggests active user community
Technical Stack
Modern tech stack aligned with sponsor technologies

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline